Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
Bert van Meurs, Chief Business Leader Image Guided Therapy and Member of the Executive Committee at Royal Philips, shared on LinkedIn:
”New late-breaking results from the iMODERN trial, presented at TCT 2025, bring important clarity for heart attack patients with multi-vessel disease.
This global study confirms that treating additional lesions during the initial procedure is just as safe as waiting to stage treatment, giving clinicians more flexibility to tailor care to each patient’s needs.
Complementary findings from the ILIAS ANOCA study also highlight the value of physiology-guided assessment and personalized therapy for patients with angina but no obstructive coronary arteries, resulting in sustained improvements in quality of life.
I’m proud that Philips solutions supported both of these impactful studies.
Together with our clinical partners, we’re helping advance evidence-based, individualized cardiovascular care for patients worldwide.”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
May 11, 2026, 14:44World Thalassaemia Day: Building Care Around Patients – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
May 11, 2026, 14:43Arun Rajasekaran: Demonstrating an Association Between Serum Anti-PLA2R Ab and Thrombosis Risk
-
May 11, 2026, 14:42Julie Makani: WHO 2026 Guidelines on the Management of Childhood Illness for SCD
-
May 11, 2026, 14:41Rikke Johannessen: Acknowledging Africa CDC Leadership in Advancing Africa’s NCD Agenda
-
May 11, 2026, 14:41Ahmed Alanazi: Understanding the Causes of Hypercoagulation
-
May 11, 2026, 14:40Katerina Pavenski: What Should Be the Future Priorities in PBM
-
May 11, 2026, 14:18Maria Cherska: The Future of Familial Hypercholesterolemia Care
-
May 11, 2026, 13:59Dino Mehic: What Clinicians May Overlook in Bleeding Disorders
-
May 11, 2026, 13:48Ney Carter Borges: POAF and Long-Term Outcomes After Cardiac Surgery